Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]

Hepatology

Volumn 45, Issue 1, 2007, Pages 258-259

  Lukasiewicz, Esther ^a   Hellstrand, Kristoffer ^b   Westin, Johan ^b   Ferrari, Carlo ^c   Neumann, Avidan U ^a   Pawlotsky, Jean Michel ^d   Schalm, Solko W ^e   Zeuzem, Stefan ^f   Veldt, Bart J ^e   Hansen, Bettina E ^e   Verhey Hart, Elke ^e   Lagging, Martin ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d HENRI MONDOR HOSPITAL   (France)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ANTIVIRAL THERAPY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; EUROPE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; MULTICENTER STUDIES; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33846445632     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21505     Document Type: Letter

References (3)

1. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006;43:954-960.
2. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005;43:250-257.
3. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre-treatment viremia. J Hepatol 2006;44:97-103.